2024
Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer
Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, PMCID: PMC11581571, DOI: 10.1001/jamanetworkopen.2024.40591.Peer-Reviewed Original ResearchConceptsProstate-specific antigenProstate-specific antigen levelPSMA-PETRecurrent prostate cancerBiochemical recurrenceProstate cancerLong-term outcomesProstate-specific membrane antigen positron emission tomographyEvaluation of biochemical recurrenceDetection of biochemical recurrenceLife yearsConventional imagingDefinitive local therapyPSMA PET imagingProstate cancer deathDetection of metastasesRetrospective cohort studyBase case analysisIncremental life-yearsPositron emission tomographyDecision-analytic modelLocal therapyConventional imaging strategiesDelayed treatmentDisease course
2023
Changes in planned disease management after piflufolastat F18 PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study.
Pouliot F, Gorin M, Rowe S, Saperstein L, Denes B, DiPippo V, Stambler N, Morris M, Siegel B. Changes in planned disease management after piflufolastat F18 PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study. Journal Of Clinical Oncology 2023, 41: 61-61. DOI: 10.1200/jco.2023.41.6_suppl.61.Peer-Reviewed Original ResearchBaseline PSA levelsPET/CTLow PSA levelsPSA levelsTreatment recommendationsDisease managementLow baseline PSA levelsBiochemically recurrent prostate cancerPositive PET/CTBaseline PSA valuePhase 3 studySubset of patientsRecurrent prostate cancerProstate cancer patientsAvailable clinical informationConventional imaging resultsYears of ageDisease management plansManagement QuestionnaireEquivocal imagingEvaluable patientsNegative PETSystemic therapyDisease recurrenceInitial staging
2021
PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) withbiochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.
Pouliot F, Gorin M, Rowe S, Saperstein L, Josephson D, Carroll P, Wong J, Pantel A, Cho S, Gage K, Piert M, Iagaru A, Pollard J, Wong V, Jensen J, Stambler N, Morris M, Siegel B. PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) withbiochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth. Journal Of Clinical Oncology 2021, 39: 5023-5023. DOI: 10.1200/jco.2021.39.15_suppl.5023.Peer-Reviewed Original ResearchF-DCFPyL PET/CTPositive predictive valuePhase 3 studyPET/CTProstate cancerPrimary endpointPSA responseF-DCFPyL PET/CT scansF-fluciclovine PET/CTProspective phase 3 studyCorrelative imaging findingsRecurrent prostate cancerPET/CT accuracyConventional imaging modalitiesClinical trial informationDefinitive therapyLocal therapyBaseline imagingMetastatic lesionsImaging findingsAnatomic lesionsLower PSAF-DCFPyLTreatment responseCT scanPSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.
Pouliot F, Gorin M, Rowe S, Saperstein L, Josephson D, Carroll P, Wong J, Pantel A, Cho S, Gage K, Piert M, Iagaru A, Pollard J, Wong V, Jensen J, Stambler N, Morris M, Siegel B. PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth. Journal Of Clinical Oncology 2021, 39: 33-33. DOI: 10.1200/jco.2021.39.6_suppl.33.Peer-Reviewed Original ResearchF-DCFPyL PET/CTPositive predictive valuePET/CTProstate cancerPrimary endpointPSA responseF-DCFPyL PET/CT scansF-fluciclovine PET/CTProspective phase 3 studyBiochemically recurrent prostate cancerCorrelative imaging findingsPhase 3 studyPhase III studyRecurrent prostate cancerPET/CT accuracyConventional imaging modalitiesDefinitive therapyIII studyLocal therapyMetastatic lesionsBaseline imagingImaging findingsAnatomic lesionsLower PSAF-DCFPyL
2020
Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR).
Morris M, Carroll P, Saperstein L, Pouliot F, Josephson D, Wong J, Pantel A, Cho S, Gage K, Piert M, Iagaru A, Pollard J, Wong V, Jensen J, Stambler N, Gorin M, Siegel B. Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR). Journal Of Clinical Oncology 2020, 38: 5501-5501. DOI: 10.1200/jco.2020.38.15_suppl.5501.Peer-Reviewed Original ResearchPET/CTProstate cancerPrimary endpointOccult diseaseSystemic therapyLocal therapyClinical managementNovel PET imaging agentBiochemically recurrent prostate cancerDrug-related SAEsEquivocal conventional imagingMetastatic prostate cancerRecurrent prostate cancerMajority of ptsBCR prostate cancerCurrent imaging modalitiesPET imaging agentCommon AEsDefinitive therapySecondary endpointsPSA responseMulticenter studyLower PSAPCa cellsF-DCFPyLLBA02-12 A MULTICENTER PHASE 3 STUDY OF PSMA-TARGETED 18 F-DCFPYL PET/CT IN MEN WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER: RESULTS FROM THE CONDOR TRIAL
Gorin* M, Siegel B, Rowe S, Saperstein L, Pouliot F, Josephson D, Wong J, Pantel A, Cho S, Gage K, Piert M, Iagaru A, Pollard J, Wong V, Jensen J, Stambler N, Morris M, Carroll P. LBA02-12 A MULTICENTER PHASE 3 STUDY OF PSMA-TARGETED 18 F-DCFPYL PET/CT IN MEN WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER: RESULTS FROM THE CONDOR TRIAL. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000958.012.Peer-Reviewed Original Research
2019
A phase III, multicenter study to assess the diagnostic performance and clinical impact of 18 F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR).
Morris M, Pouliot F, Saperstein L, Rowe S, Gorin M, Josephson D, Wong J, Carroll P, Lin T, Stambler N, Wong V, Jensen J, Siegel B. A phase III, multicenter study to assess the diagnostic performance and clinical impact of 18 F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR). Journal Of Clinical Oncology 2019, 37: tps5093-tps5093. DOI: 10.1200/jco.2019.37.15_suppl.tps5093.Peer-Reviewed Original ResearchF-DCFPyL PET/CTPET/CTRecurrent prostate cancerMetastatic prostate cancerProstate cancerF-DCFPyLPositron emission tomographyClinical impactDiagnostic performancePET/CT resultsEquivocal conventional imagingOpen-label studyWhole-body PET/CTProstate-specific membrane antigenYears of ageUnmet diagnostic needsEligible patientsF-fluciclovineDefinitive therapyBaseline PSAMulticenter studyDetection rateProstate adenocarcinomaPatient managementC-choline